Table 2.
Treatment details and treatment related toxicity
| Radiotherapy (RT) techniquea, N (%) | |
| 2D RT | 1 (1.3) |
| 3D conformal RT | 64 (81.0) |
| IMRT | 3 (3.8) |
| VMAT | 11 (13.9) |
| Dose, median (min–max)b | 39.0 Gy (3–66) |
| Course of RT, N (%) | |
| Intended RT complete | 55 (69.6) |
| Intended RT incomplete | 24 (30.4) |
| Death during RT | 17 (21.5) |
| Symptom relief: all patients | 54 (68.4) |
| Symptom relief: patients with intended RT complete | 49 (89.1) |
| Change to curative concept | 13 (16.5) |
| Target volume (TV) features | |
| Size of CTV (ml), median (min–max)c | 387 (89.5–1966.2) |
| Size of PTV (ml), median (min–max)c | 992.9 (288.5–3659.6) |
| TV adjusted during therapy, N (%) | 18 (22.8) |
|
Adjusted TV smaller than initial TV N (%) |
10 (55.6 referring to above) |
| Acute treatment-related side effectsd, N (%) | |
| Grade 1 | 30 (38.0) |
| Grade 2 | 7 (8.9) |
| Radiation induced pneumonitis | 2 (2.5) |
| Systemic therapy, N (%) | |
| Concomitant chemotherapy | 15 (19.0) |
| Chemotherapy, any | 53 (67.1) |
| Immunotherapy, any | 8 (10.1) |
IMRT intensity-modulated radiotherapy, VMAT volumetric modulated arc therapy, TV target volume, CTV clinical target volume, PTV planning target volume, RT radiotherapy
aHigh proportion of 3D conformal RT due to fast planning approach in order to deliver rapid treatment (usually, 2‑3 h after consulting the patient)
bRadiotherapy for superior vena cava syndrome only. For details, refer to Table 3
cNot applicable in 1 patient due to 2D radiotherapy (see above)
dAcute toxicity as scored by Common Terminology Criteria for Adverse Events, v.5 [21]. There was no toxicity exceeding grade 2